MetaCap

Cingulate (CING) vs MAIA Biotechnology (MAIA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cingulate (CING) has outperformed MAIA Biotechnology (MAIA) over the past year, gaining 27.8% versus a gain of 21.7%. MAIA Biotechnology is the larger company by market cap ($68.5 million vs $67.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CING+27.76%MAIA+21.71%
+242%+115%-12%
Nov 21, 20251 yearNov 20, 2026
CING-98.47%MAIA-80.86%
+58%-24%-107%
Jul 25, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CING versus MAIA key metrics
MetricCINGMAIA
Share price$4.51$1.11
Market cap$67.48M$68.54M
1-day change-14.26%-2.63%
YTD return+3.92%-27.45%
1-year return+27.76%+21.71%
EPS (TTM)$-2.67$-0.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-22.45M$-22.40M
52-week high$11.89$3.19
52-week low$3.16$0.895
Distance from 52-week high-62.07%-65.20%
Analyst consensusnonenone
Avg. price target upside+370.07%+981.08%
Average volume178.82K524.29K
Shares outstanding14.96M61.75M
Employees1413
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cingulate

CING stock →

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About MAIA Biotechnology

MAIA stock →

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

CING vs MAIA FAQ

Which is bigger, Cingulate or MAIA Biotechnology?

MAIA Biotechnology (MAIA) is larger, with a market capitalization of $68.54M compared with $67.48M for Cingulate (CING).

Which stock has performed better over the past year, CING or MAIA?

CING returned +27.76% over the past 12 months, compared with +21.71% for MAIA (price return, excluding dividends). Past performance does not predict future results.

Are Cingulate and MAIA Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons